To evaluate the above conclusions in a relevant clinical setting, we analyzed the expression of TCF4 by immunohistochemistry (IHC) in paired pre- and post-therapy tumor or metastasis samples from 21 breast cancer patients treated with fluoracil-containing chemotherapies. The gene discussed is TCF4; the disease is breast carcinoma.